Naturland Holding ZrtBUD:NATURLAND 61 Debt-to-Equity is 0.05 as of Jun. 2025, which is 17% below its 10-year median of 0.06. GuruFocus rates BUD:NATURLAND with a GF Score™ of 61/100 and a GF Value™ of Ft2,889.17 (Fairly Valued). The stock has 5 warning signs investors should review. Among 812 Drug Manufacturers companies, Naturland Holding Zrt ranks better than 82.39% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Naturland Holding Zrt's Debt-to-Equity or its related term are showing as below:
BUD:NATURLAND'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.06 Max: 0.16
Current: 0.05
During the past 5 years, the highest Debt-to-Equity Ratio of Naturland Holding Zrt was 0.16. The lowest was 0.05. And the median was 0.06.
BUD:NATURLAND's Debt-to-Equity is ranked better than 82.39% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs BUD:NATURLAND: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Naturland Holding Zrt Debt-to-Equity Related Terms
Naturland Holding Zrt Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Naturland Holding Zrt's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NATURLAND vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturland Holding Zrt Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Naturland Holding Zrt's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naturland Holding Zrt (BUD:NATURLAND) has a Debt-to-Equity of 0.05 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Naturland Holding Zrt and its competitors. This is 17% below median its historical median of 0.06. Over the past decade, Naturland Holding Zrt's Debt-to-Equity has ranged from 0.05 to 0.16. According to the industry distribution chart, Naturland Holding Zrt ranks #143 out of 812 companies in the Drug Manufacturers industry, placing it in the top 17.6%.
Is Naturland Holding Zrt's Debt-to-Equity too high?
Naturland Holding Zrt's current Debt-to-Equity of 0.05 is 17% below median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.16. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Naturland Holding Zrt's value of 0.05 is 81.5% below this industry median. Based on the distribution chart, Naturland Holding Zrt ranks #143 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Naturland Holding Zrt ranks #143 out of 812 companies for Debt-to-Equity. This places Naturland Holding Zrt in the top 18% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Naturland Holding Zrt's value of 0.05 is 81.5% below this benchmark. Historically, Naturland Holding Zrt's own Debt-to-Equity has ranged from 0.05 to 0.16 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 0.27, Naturland Holding Zrt has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturland Holding Zrt's current Debt-to-Equity of 0.05 is 81.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Naturland Holding Zrt and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturland Holding Zrt's current Debt-to-Equity is 0.05, which is 17% below median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,889.17, compared to a current price of Ft2,740.00 — trading 5.2% below its estimated fair value. The current Debt-to-Equity is 0.05, which is 17% below median its 10-year median of 0.06 and 81.5% below the Drug Manufacturers industry median of 0.27. Naturland Holding Zrt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current Debt-to-Equity is 0.05 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued.
The current stock price of Ft2,740.00 is trading 5.2% below its estimated GF Value™ of Ft2,889.17.
GuruFocus considers Naturland Holding Zrt to be Fairly Valued.
Key valuation signals for BUD:NATURLAND:
Debt-to-Equity: 0.05 (17% below median its 10-year median of 0.06)
GF Value™: Ft2,889.17 vs. price of Ft2,740.00 (5.2% below fair value)
Industry Position: 81.5% below the Drug Manufacturers median (#143 of 812)
No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score
Get the complete analysis for BUD:NATURLAND
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NATURLAND has been successfully added to your 
